Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T21:52:07.963Z.
Calculation as of: 2026-10-06T21:52:07.963Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 764f42141b21779aba3712b54ee9373bee46ed3fd4a49ef41b5b57d04fae8ed9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$239.01M
EV/EBITDA Ratio
12.88x
TTM Avg
20.89x
3Y Avg
46.57x
5Y Avg
889.74x
Market Cap
$239.02M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$235.97M
EV/EBITDA Ratio
N/A
TTM Avg
5.07x
3Y Avg
4.97x
5Y Avg
6.62x
Market Cap
$235.66M
EV/EBITDA Ratio
N/A
TTM Avg
21.13x
3Y Avg
83.14x
5Y Avg
83.14x
Market Cap
$235.08M
EV/EBITDA Ratio
18.54x
TTM Avg
9.66x
3Y Avg
8.05x
5Y Avg
8.98x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Invivyd, Inc. (IVVD) | $237.57M | N/A | N/A | N/A | N/A |
| BioAge Labs Inc. (BIOA)vs › | $236.82M | N/A | N/A | N/A | N/A |
| High Tide Inc. (HITI)vs › | $239.01M | 12.88x | 20.89x | 46.57x | 889.74x |
| Century Therapeutics, Inc. (IPSC)vs › | $239.02M | N/A | N/A | N/A | N/A |
| SIGA Technologies, Inc. (SIGA)vs › | $235.97M | N/A | 5.07x | 4.97x | 6.62x |
| Akebia Therapeutics, Inc. (AKBA)vs › | $235.66M | N/A | 21.13x | 83.14x | 83.14x |
| Utah Medical Products, Inc. (UTMD)vs › | $235.08M | 18.54x | 9.66x | 8.05x | 8.98x |
| Quantum-Si incorporated (QSI)vs › | $241.34M | N/A | N/A | N/A | N/A |
| Q32 Bio Inc. (QTTB)vs › | $241.39M | 6.41x | 4.45x | 4.45x | 4.45x |
| Lifecore Biomedical, Inc. (LFCR)vs › | $241.94M | N/A | 28.93x | 31.09x | 27.66x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
